Evidence map›Paper›PMID 24650561›Full record

ArticleThe American journal of pathology2014

Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation.

Kye-Im Jeon, Ajit Kulkarni, Collynn F Woeller, Richard P Phipps, Patricia J Sime, Holly B Hindman, Krystel R Huxlin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Diabetic keratopathy and nuclear proteins (Review).Molecular medicine reports · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Lobeglitazone attenuates fibrosis in corneal fibroblasts by interrupting TGF-beta-mediated Smad signaling.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kye-Im JeonFlaum Eye Institute, University of Rochester, Rochester, New York.
Ajit KulkarniDepartment of Medicine, University of Rochester, Rochester, New York.
Collynn F WoellerDepartment of Environmental Medicine, University of Rochester, Rochester, New York.
Richard P PhippsFlaum Eye Institute, University of Rochester, Rochester, New York; Department of Medicine, University of Rochester, Rochester, New York; Department of Environmental Medicine, University of Rochester, Rochester, New York.
Patricia J SimeDepartment of Medicine, University of Rochester, Rochester, New York; Department of Environmental Medicine, University of Rochester, Rochester, New York.
Holly B HindmanFlaum Eye Institute, University of Rochester, Rochester, New York; Center for Visual Science, University of Rochester, Rochester, New York.
Krystel R HuxlinFlaum Eye Institute, University of Rochester, Rochester, New York; Center for Visual Science, University of Rochester, Rochester, New York. Electronic address: huxlin@cvs.rochester.edu.
University of Rochester · US

Funding

VISUAL SCIENCE RESEARCH CTR SUPPORTP30EY001319 · UNIVERSITY OF ROCHESTER · 1985 to 2025
$3.7M
Multidisciplinary Training in Pulmonary ResearchT32HL066988 · UNIVERSITY OF ROCHESTER · 2001 to 2005
$2.0M
Corneal wound healing: ocular optics after laser surgeryR01EY015836 · UNIVERSITY OF ROCHESTER · 2004 to 2005
$695k
Modulation of Silica-Induced Pulmonary FibrosisR01HL075432 · UNIVERSITY OF ROCHESTER · 2005 to 2005
$351k
NEI NIH HHS EY015836NEI NIH HHS EY017123NEI NIH HHS K23 EY019353NEI NIH HHS P30 EY001319NEI NIH HHS R01 EY015836NEI NIH HHS R01 EY017123NHLBI NIH HHS HL75432NHLBI NIH HHS R01 HL075432NHLBI NIH HHS T32 HL066988
6 · The paper itself

Abstract

Corneal scarring, whether caused by trauma, laser refractive surgery, or infection, remains a significant problem for humans. Certain ligands for peroxisome proliferator-activated receptor gamma (PPARγ) have shown promise as antiscarring agents in a variety of body tissues. In the cornea, their relative effectiveness and mechanisms of action are still poorly understood. Here, we contrasted the antifibrotic effects of three different PPARγ ligands (15-deoxy-Δ12,14-prostaglandin J2, troglitazone, and rosiglitazone) in cat corneal fibroblasts. Western blot analyses revealed that all three compounds reduced transforming growth factor (TGF)-β1-driven myofibroblast differentiation and up-regulation of α-smooth muscle actin, type I collagen, and fibronectin expression. Because these effects were independent of PPARγ, we ascertained whether they occurred by altering phosphorylation of Smads 2/3, p38 mitogen-activated protein kinase, stress-activated protein kinase, protein kinase B, extracellular signal-regulated kinase, and/or myosin light chain 2. Only p38 mitogen-activated protein kinase phosphorylation was significantly inhibited by all three PPARγ ligands. Finally, we tested the antifibrotic potential of troglitazone in a cat model of photorefractive keratectomy-induced corneal injury. Topical application of troglitazone significantly reduced α-smooth muscle actin expression and haze in the stromal ablation zone. Thus, the PPARγ ligands tested here showed great promise as antifibrotics, both in vitro and in vivo. Our results also provided new evidence for the signaling pathways that may underlie these antifibrotic actions in corneal fibroblasts.

Indexed as

ActinsAnimalsCatsCell Line, TransformedCell NucleusChromansCollagen Type ICorneaFibronectinsFibrosisHumansLigandsMyofibroblastsp38 Mitogen-Activated Protein KinasesPhosphorylationPPAR gamma9-deoxy-delta-9-prostaglandin D2ActinsChromansCollagen Type IFibronectinsLigandsp38 Mitogen-Activated Protein KinasesPPAR gammaProstaglandin D2Protein Kinase InhibitorsRosiglitazoneSmad ProteinsThiazolidinedionesTransforming Growth Factor beta1Troglitazone

Identifiers

PMID24650561
PMCPMC4005981
OpenAlexW2087110345

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.